<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791149</url>
  </required_header>
  <id_info>
    <org_study_id>PI2022_843_0042</org_study_id>
    <nct_id>NCT05791149</nct_id>
  </id_info>
  <brief_title>Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity</brief_title>
  <acronym>EPSACO</acronym>
  <official_title>Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Head and neck squamous cell carcinoma (HNSCC) are malignant tumors originating from the&#xD;
      epithelial mucosa of the upper aerodigestive tract. The oral cavity is the most frequent&#xD;
      location of HNSCC (oral squamous cell carcinoma: OSCC). Tobacco use and alcohol consumption&#xD;
      are the greatest risk factors. The Hauts de France region has one of the highest incidence&#xD;
      rates of OSCC. The overall survival of patients with OSCC remains low, with a 5-year overall&#xD;
      survival rate of around 60%. In addition to the oncological prognosis, OSCCs and their&#xD;
      treatment have a significant impact on the quality of life of patients. An early diagnosis of&#xD;
      OSCC is recommended, but it remains difficult. It can be for example challenging to diagnose&#xD;
      OSCC in a context of oral premalignant lesions. Identifying objective biomarkers of&#xD;
      malignancy would be an advantage and would allow better progress in the field of precision&#xD;
      medicine and surgery for these tumors.&#xD;
&#xD;
      The investigators propose to establish the diagnostic use of an optimized DNA methylation&#xD;
      profile detected in the saliva of OSCC patients by comparing these epigenetic marks before&#xD;
      and after tumor resection.&#xD;
&#xD;
      The investigators will construct a consolidated signature of 4 genes whose DNA is subject to&#xD;
      methylation and gene expression is restricted to cancer cells, by crossing TCGA analysis with&#xD;
      single-cell analysis (single-cell RNA sequencing).&#xD;
&#xD;
      The investigators propose to analyse DNA methylation of the corresponding genes in the saliva&#xD;
      of n=30 OSCC patients recruited for primary surgical resection in the Department of&#xD;
      Maxillofacial Surgery vs controls. In addition, the investigators will examine the&#xD;
      methylation profiles before / after complete excisional surgery of OSCC. This pilot study&#xD;
      will aim to validate the analysis of DNA methylation markers in saliva of OSCC, with the aim&#xD;
      of improving the diagnostic precision of OSCC and, secondly, to compare these markers before&#xD;
      and after treatment by primary surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2022</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of methylated gene in both groups : control and OSCC patients</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of methylated gene in OSCC patients before surgery</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of methylated gene in OSCC patients after surgery</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Oral Squamous Cell Carcinoma</condition>
  <condition>Maxillo-facial Surgery</condition>
  <condition>Biomarkers</condition>
  <condition>Saliva</condition>
  <condition>DNA Methylation</condition>
  <condition>Epigenetics</condition>
  <arm_group>
    <arm_group_label>OSCC patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>saliva tube</intervention_name>
    <description>1 tube of saliva (~2 ml) will be collected from all patients enrolled in the study. For operated OSCC patients a second tube will be collected during the routine hospital visit 4 weeks after surgery</description>
    <arm_group_label>OSCC patients</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient group:&#xD;
&#xD;
          -  Patients from the maxillofacial surgery department treated for a histologically&#xD;
             confirmed squamous cell carcinoma of the oral cavity&#xD;
&#xD;
          -  Patients whose first-line treatment decision at the multidisciplinary meeting in the&#xD;
             service of Maxillofacial Surgery is surgery&#xD;
&#xD;
          -  Patients who have not yet been treated surgically or by neoadjuvant treatment&#xD;
&#xD;
          -  Patients over 18 years old&#xD;
&#xD;
          -  Patients who have provided free and informed consent in writing&#xD;
&#xD;
          -  Patients benefiting from a social security scheme&#xD;
&#xD;
        Control group:&#xD;
&#xD;
          -  Patients in the maxillofacial surgery department not covered for head and neck cancer&#xD;
&#xD;
          -  Patients over 18 years old&#xD;
&#xD;
          -  Patients who have provided free and informed consent in writing&#xD;
&#xD;
          -  Patients benefiting from a social security scheme&#xD;
&#xD;
          -  Control group homogeneous with the patient group according to age, sex, tobacco and&#xD;
             alcohol consumption&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with other types of cancer&#xD;
&#xD;
          -  Patients under the age of 18&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patients under guardianship, curators, legal protection or deprived of liberty&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zuzana SAIDAK, PhD</last_name>
    <phone>03 22 08 70 84</phone>
    <email>saidak.zuzana@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amiens University Hospital</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzana Saidak, MD</last_name>
      <phone>03 22 08 70 84</phone>
      <email>saidak.zuzana@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie Dakpé, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie Testelin, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe Attencourt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine Galmiche</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 17, 2023</last_update_submitted>
  <last_update_submitted_qc>March 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Squamous Cell Carcinoma</keyword>
  <keyword>Maxillo-facial surgery</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Saliva</keyword>
  <keyword>DNA Methylation</keyword>
  <keyword>epigenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

